Document is current
Any future updates will be listed below
-
Authors
Reason, Ellery H.
Aiduk, Michael D.
Nash, Amanda L.
McDuff, Susan G. R.
Renner, Derrick
Kollipara, Rahul Krishna
Satta, Sandro
Velichko, Sharlene
Kalashnikova, Ekaterina
Rodriguez, Angel A.
Liu, Minetta C.
Strickler, John H.
Grilley-Olson, Juneko E.
Rosenberger, Laura H. https://orcid.org/0000-0002-6829-6747
-
Funding
Funding for this research was provided by:
This study was supported by philanthropic funds through the generosity of the Donor Network of Rachel Boyle Lee-Ashley.
- License Information
-
More Information
Article History
Received: 30 April 2025
Accepted: 27 June 2025
First Online: 23 July 2025
Disclosure
: This study was supported by philanthropic funds through the generosity of the Donor Network of Rachel Boyle Lee-Ashley. E.H.R., M.D.A., A.L.N., S.G.R.M., and L.H.R have nothing to disclose. J.H.S. reports consultant or advisory role (personal): Abbvie, Amgen, Astellas, AstraZeneca, Bayer, BeOne, BMS, Cytovation, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Incyte, Ipsen, Johnson and Johnson, Jazz Pharmaceuticals, Leap, Merck, Natera, Pfizer, Quanta Therapeutics, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, Xilio Therapeutics, and Triumvira Immunologics (stock options); research funding or contracted research (institution): Abbvie, Amgen, Apollo Therapeutics, Bayer, BeOne, Daiichi-Sankyo, Eli Lilly, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, Roche/Genentech, and JEGO; research funding or contracted research (research): Polaris pharmaceuticals, Inhibrx, Boehringer Ingelheim, and Abbisko; research funding or contracted research (consulting): Deciphera and Ipsen. D.R., S.V., A.A.R., M.C.L., and C.C.P. are employees with Natera, Inc. and have stock in Natera, Inc.
